Phibro Animal Health (PAHC) EBIT (2012 - 2026)

Phibro Animal Health's EBIT history runs 15 years deep, the most recent figure standing at $44.7 million for Q1 2026.

• On a quarterly basis, EBIT rose 33.23% year-over-year to $44.7 million in Q1 2026; TTM through Mar 2026 was $180.0 million, a 89.1% increase from a year earlier, with the FY2025 full-year figure at $110.5 million, up 107.19% from the prior year.
• EBIT retreated to $44.7 million in Q1 2026 per PAHC's latest filing, from $50.3 million in the prior quarter.
• Across five years, EBIT topped out at $51.3 million in Q3 2025 and bottomed at -$726000.0 in Q3 2023.
• The 5-year median for EBIT is $19.9 million (2024), against an average of $24.9 million.
• Across the five-year window, EBIT plunged 105.31% in 2023 and jumped 2537.88% in 2024, its largest moves.
• Year by year, EBIT stood at $15.8 million in 2022, then declined by 0.9% to $15.7 million in 2023, then jumped by 62.62% to $25.5 million in 2024, then surged by 97.1% to $50.3 million in 2025, then slipped by 11.27% to $44.7 million in 2026.
• Per Business Quant, the three latest PAHC EBIT figures stand at $44.7 million (Q1 2026), $50.3 million (Q4 2025), and $51.3 million (Q3 2025).